NZ589764A - NMDA receptor antagonists for the treatment of neuropsychiatric disorders - Google Patents

NMDA receptor antagonists for the treatment of neuropsychiatric disorders

Info

Publication number
NZ589764A
NZ589764A NZ589764A NZ58976409A NZ589764A NZ 589764 A NZ589764 A NZ 589764A NZ 589764 A NZ589764 A NZ 589764A NZ 58976409 A NZ58976409 A NZ 58976409A NZ 589764 A NZ589764 A NZ 589764A
Authority
NZ
New Zealand
Prior art keywords
treatment
neuropsychiatric disorders
receptor antagonists
nmda receptor
formula
Prior art date
Application number
NZ589764A
Other languages
English (en)
Inventor
Raymond J Dingledine
Stephen F Traynelis
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of NZ589764A publication Critical patent/NZ589764A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ589764A 2008-05-09 2009-05-11 NMDA receptor antagonists for the treatment of neuropsychiatric disorders NZ589764A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12709808P 2008-05-09 2008-05-09
PCT/US2009/043502 WO2009137843A2 (en) 2008-05-09 2009-05-11 Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
NZ589764A true NZ589764A (en) 2012-10-26

Family

ID=41265475

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ589764A NZ589764A (en) 2008-05-09 2009-05-11 NMDA receptor antagonists for the treatment of neuropsychiatric disorders

Country Status (16)

Country Link
US (1) US20110160223A1 (enExample)
EP (1) EP2296658A4 (enExample)
JP (1) JP2011520815A (enExample)
KR (1) KR20110016891A (enExample)
CN (1) CN102762207A (enExample)
AU (1) AU2009244082A1 (enExample)
BR (1) BRPI0912362A2 (enExample)
CA (1) CA2722776A1 (enExample)
CO (1) CO6341558A2 (enExample)
EA (1) EA020339B1 (enExample)
IL (1) IL208895A0 (enExample)
MX (1) MX2010012186A (enExample)
NZ (1) NZ589764A (enExample)
SG (1) SG195568A1 (enExample)
WO (1) WO2009137843A2 (enExample)
ZA (1) ZA201007958B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120123089A (ko) 2010-02-16 2012-11-07 화이자 인코포레이티드 5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2013170072A2 (en) * 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
US8974365B2 (en) * 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
FI3932932T3 (fi) 2013-03-13 2025-10-15 Sage Therapeutics Inc Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
US20160368897A1 (en) 2013-06-28 2016-12-22 Emory University Pyrazoline Dihydroquinolones, Pharmaceutical Compositions, and Uses
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
BR112017007053A2 (pt) * 2014-10-07 2018-06-19 Sage Therapeutics Inc compostos neuroativos e métodos de utilização deste composto.
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233077B1 (en) 2014-12-19 2026-05-06 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DK3812392T3 (da) 2015-07-06 2025-07-21 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
PT3319611T (pt) 2015-07-06 2021-04-22 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
WO2017093354A1 (en) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Nmdar antagonists for the treatment of diseases associated with angiogenesis
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
DK3529257T3 (da) 2016-10-18 2023-08-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
WO2019071394A1 (zh) * 2017-10-09 2019-04-18 华南农业大学 一种抗白色念珠菌的新型化合物及其制备方法和应用
US11981652B2 (en) 2018-03-28 2024-05-14 Emory University GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
CN114539129B (zh) * 2020-11-18 2023-06-09 上海中医药大学附属龙华医院 烯丙胺类双功能化合物及其用途
JP2024533182A (ja) 2021-09-02 2024-09-12 エモリー ユニバーシティー 酸性ｐＨで増強された効力を有するＮ－メチル－Ｄ－アスパラギン酸受容体のＧｌｕＮ２Ｂサブユニット選択的アンタゴニスト

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
EP0005828B1 (de) * 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2824677A1 (de) * 1978-06-06 1979-12-20 Hoechst Ag Neue substituierte phenylpiperazinderivate und verfahren zu deren herstellung
JPS55162774A (en) * 1979-06-06 1980-12-18 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649362A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Thiocarbostyril derivative
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS579769A (en) * 1980-06-23 1982-01-19 Otsuka Pharmaceut Co Ltd 2-benzimidazolinone derivative
JPS58203968A (ja) * 1982-05-21 1983-11-28 Otsuka Pharmaceut Co Ltd イソカルボスチリル誘導体
CN85108214A (zh) * 1984-11-22 1986-08-20 赫彻斯特股份公司 新的取代的苯基哌嗪衍生物及其药物的制造方法
JPS62252783A (ja) * 1986-02-13 1987-11-04 ワ−ナ−−ランバ−ト・コンパニ− ベンズ複素環式化合物
GB9005318D0 (en) * 1990-03-09 1990-05-02 Isis Innovation Antiarrhythmic agents
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
WO1999023072A1 (en) * 1997-10-31 1999-05-14 Suntory Limited Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
AU2001296994A1 (en) * 2000-10-06 2002-04-15 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
DE10248925A1 (de) * 2002-10-15 2004-04-29 Proteosys Ag Neue Verbindungen mit dopaminerger und/oder serotoninerger Aktivität
EP1626722A1 (en) * 2003-05-16 2006-02-22 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
UA80055C2 (en) * 2003-05-27 2007-08-10 Forest Laboratories Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment
HUP0401526A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use
JP5015779B2 (ja) * 2004-08-23 2012-08-29 エモリー・ユニバーシテイ インビボ治療のためのｐＨ依存性化合物の改良選択法
US20080200498A1 (en) * 2005-07-12 2008-08-21 Angelo Ceci Pharmaceutical Composition For The Treatment Of Disorders Of Sexual Desire
TWI329641B (en) * 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
EP2520567A3 (en) * 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
KR20100045983A (ko) * 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질

Also Published As

Publication number Publication date
EA201071291A2 (ru) 2011-04-29
KR20110016891A (ko) 2011-02-18
EP2296658A4 (en) 2014-01-15
WO2009137843A2 (en) 2009-11-12
EA020339B1 (ru) 2014-10-30
BRPI0912362A2 (pt) 2015-10-06
CN102762207A (zh) 2012-10-31
JP2011520815A (ja) 2011-07-21
MX2010012186A (es) 2011-02-22
IL208895A0 (en) 2011-01-31
EP2296658A2 (en) 2011-03-23
ZA201007958B (en) 2011-07-27
SG195568A1 (en) 2013-12-30
CO6341558A2 (es) 2011-11-21
CA2722776A1 (en) 2009-11-12
US20110160223A1 (en) 2011-06-30
WO2009137843A9 (en) 2010-03-11
AU2009244082A1 (en) 2009-11-12
EA201071291A3 (ru) 2014-02-28

Similar Documents

Publication Publication Date Title
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
GEP20156319B (en) Asymmetric ureas and medical uses thereof
MX346186B (es) Inhibidores de proteina cinasas.
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
MX361542B (es) Compuestos de morfinan.
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
CA2725933A1 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
TW200728307A (en) Novel spirochromanone derivatives
PH12013500880A1 (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators
MX2014006027A (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
GEP20146125B (en) Aminopyrimidines as syk inhibitors
GEP20156351B (en) Glucagon receptor modulator
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
SI2150530T1 (sl) Substituirani sulfonamidni derivati
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
WO2012040636A3 (en) Compounds and methods for treating diseases mediated by protease activated receptors
GEP201606526B (en) 5-ht3 receptor antagonists
MX2014007878A (es) Formulaciones de (+) - 2 - [1 - (3 - etoxi - 4 - metoxi - fenil) - 2 - metansulfonil - etil] - 4 - acetil aminoisoindolin - 1, 3 - diona.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 MAY 2016 BY AJ PARK

Effective date: 20130529

LAPS Patent lapsed